Liberator Medical Holdings, Inc. is a medical device company specializing in the design, development, manufacture and distribution of respiratory support and oxygen therapy products. The company’s product portfolio includes non‐invasive ventilators, auto‐adjusting positive airway pressure (PAP) devices, portable oxygen concentrators and oxygen conservation systems. These solutions are used by patients suffering from sleep apnea, chronic obstructive pulmonary disease (COPD) and other respiratory disorders in homecare settings and long‐term care facilities.
Key products in Liberator Medical’s lineup include advanced auto‐CPAP and BiPAP systems featuring ramp technology and integrated data logging, as well as lightweight, battery‐powered oxygen concentrators designed for ambulatory use. The company markets its equipment through a network of durable medical equipment (DME) providers, respiratory therapy clinics and specialized distributors. Clinical support services and training programs for healthcare providers are also offered to ensure proper device setup and patient adherence.
Founded in the late 1970s and headquartered in the western United States, Liberator Medical has grown organically and through strategic acquisitions to broaden its product offerings and geographic reach. Manufacturing operations and engineering facilities are located domestically, while distribution centers in key regions support timely order fulfillment across North America. The company continues to explore select international markets to extend access to its respiratory technologies.
Liberator Medical is led by an experienced executive management team with deep expertise in medical device development and respiratory care. Under the direction of its chief executive officer, the company maintains a focus on innovation, regulatory compliance and customer service. Ongoing research and development initiatives aim to enhance portability, usability and connectivity in its next‐generation respiratory therapy devices, positioning Liberator Medical for continued growth in an expanding market of patients with chronic respiratory conditions.
AI Generated. May Contain Errors.
Free LBMH Stock Alerts